非小细胞肺癌中常见驱动基因及其靶向药物的研究进展  

Research Progress of Common Driver Genes and Their Targeted Drugs in Non-small Cell Lung Carcinoma

作　　者：徐乐乐 彭浩[2] XU Lele;PENG Hao(Clinical Medical College,Kunming University of Science and Technology,Kunming 650000,China;Department of Thoracic Surgery,the First People′s Hospital of Yunnan Province,Kunming 650000,China)

机构地区：[1]昆明理工大学医学院,昆明650000 [2]云南省第一人民医院胸外科,昆明650000

出　　处：《医学综述》2022年第11期2152-2158,共7页Medical Recapitulate

摘　　要：随着分子生物学技术的发展,在过去的数年中,针对靶向致癌基因驱动程序的研究越来越深入,这使得非小细胞肺癌(NSCLC)的治疗从传统的细胞毒性治疗逐步转变为以肿瘤分子分型为主的靶向治疗。目前,临床上常规推荐对诊断为肺腺癌的患者进行驱动基因检测,针对存在确切驱动基因改变的患者,则可优先选择分子靶向药物治疗以期获得更好的临床疗效。已发现多种NSCLC相关突变基因,但其中存在靶向药物治疗的并不多。分析NSCLC中常见的驱动基因及其靶向药物的研究进展,可为该领域的研究提供一定帮助。In the past few years,with the development of molecular biology technology,the research on targeting oncogene drivers has become deeper and deeper,which has gradually transformed the treatment of non-small cell lung carcinoma(NSCLC)from traditional cytotoxic therapy to targeted therapy based on tumor molecular typing.Currently,driver gene testing is routinely recommended for patients diagnosed with lung adenocarcinoma.For patients with definite targeted gene changes,molecularly targeted drug therapy can be preferentially selected in order to obtain better clinical efficacy.A variety of NSCLC-related mutant genes have been found,but not many of them have targeted drugs.Analysis on the research progress of common driver genes and their targeted drugs in NSCLC,can provide certain help for the research in this field.

关 键 词：非小细胞肺癌 肺腺癌 驱动基因 靶向治疗 靶向药物 

分 类 号：R734.2[医药卫生—肿瘤]